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Summary
 
Anti-Ro60 autoantibodies are found in a variety of autoimmune disorders including systemic
lupus erythematosus (SLE), Sjögren’s syndrome, primary biliary cirrhosis, and active hepatitis.
They are the most prevalent autoantibodies in normal individuals and in asymptomatic mothers
of infants afflicted with neonatal lupus. In the present study, immune responses to recombinant
human Ro60 (rhRo60) and recombinant mouse Ro60 (rmRo60) and selected Ro60 peptides
in non–SLE-prone mice were investigated. Multiple T and B cell epitopes were identified in
Ro60. Immunizations with either xenogeneic or autologous Ro60 induced autoantibodies to a
diverse group of autoantigens. In addition to La and Ro52, proteins in the small nuclear ribo-
nucleoprotein (snRNP) particles such as SmA, SmB, SmD, and 70-kD U1-RNP were unex-
pectedly identified as targeted antigens. In the studies involving synthetic Ro60 peptides, both
 
human and mouse Ro60
 
316–335
 
 peptides, which differ in three amino acids, were found to con-
tain dominant cross-reactive T cell determinants. Immunizations with these peptides induced
autoantibodies to Ro60, La, SmD, and 70-kD U1-RNP without autoantibodies to Ro52,
SmA, or SmB. With human Ro60
 
316–335
 
 as the immunogen, additional autoantibodies reactive
with the Golgi complex were found. In contrast to the immunodominance of both human and
mouse Ro60
 
316–335
 
 peptides, the T cell determinant in human Ro60
 
441–465
 
 was dominant,
whereas that in the mouse peptide was cryptic. Immunization with human Ro60
 
441–465
 
 induced
primarily anti-peptide Abs. Mouse Ro60
 
441–465
 
 failed to induce an antibody response. These re-
sults show that both the nature of the immunogen and the immunogenicity of the related en-
dogenous antigen are important in determining the specificities of the autoantibodies gener-
ated. They have significant implications for proposed mechanisms on the generation of
complex patterns of autoantibodies to a diverse group of autoantigens in SLE patients.
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S
 
ystemic lupus erythematosus (SLE)
 
1
 
 is an autoimmune
disorder with antinuclear Abs as a prominent feature
(1–3). Among the targeted autoantigens in this disease,
Ro60 (or Sjögren’s syndrome A, SS-A) and La (SS-B),
which are physically associated with hYRNAs, constitute a
major class of SLE-related autoantigens, and Abs to them
have been shown to be associated with specific clinical pre-
sentations (2, 4). The presence of Abs to these autoantigens
in normal individuals and in asymptomatic mothers of in-
fants affected with neonatal lupus suggests that there is a
lack of tolerance to these autoantigens or that the tolerance
can be readily broken. In this regard, autoantibodies to
Ro60 and La have been induced in non–SLE-prone mice
by immunizations with recombinant proteins (5–8).
Recently, this antigenic system has been utilized to show
the role of intramolecular and intermolecular epitope
spreading in the diversification of the autoimmune re-
 
1
 
Abbreviations used in this paper:
 
 ANA, antinuclear antibody; DHFR, dihy-
drofolate reductase; LNC, lymph node cell; MAP, multiple antigenic
peptides; rhRo60, recombinant human Ro60; rmRo60, recombinant
mouse Ro60; SI, stimulation index; SLE, systemic lupus erythematosus;
SS-A, Sjögren’s syndrome-A; SS-B, Sjögren’s syndrome-B; snRNP, small
nuclear ribonucleoproteins. 
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sponse to these antigens (5–10). Because of the availability
of mouse as well as human recombinant proteins, La has
been used extensively as the immunogen in many of these
studies. In particular, emphasis has been made by Reynolds
et al. (6) that there is hierarchical self-tolerance to T cell
determinants (epitopes) within La and that cryptic or non-
dominant T cell epitopes are capable of breaking tolerance,
leading to a diversified autoantibody response.
Because of the observation that the most prevalent au-
toantibodies in asymptomatic normal individuals are anti-
Ro60 Abs (4), it is of considerable interest to explore the
immune response to this autoantigen in normal non–SLE-
prone mice. In this investigation, the immune responses to
both autologous and rhRo60 in mice were studied. These
responses involve multiple T and B epitopes within the im-
munogens. In addition to the induction of Ab to La and
Ro52, these responses unexpectedly generated autoanti-
bodies to multiple proteins in the small nuclear ribonucleo-
protein (snRNP) particle. Evidence has been obtained that
tolerance to the dominant T cell epitopes in Ro60 can be
readily overcome, leading to a diverse autoimmune response.
 
Materials and Methods
 
Cloning and Expression of Recombinant Antigens.
 
The cDNAs
encoding human Ro60, 70 kD U1-RNP (gifts from Jack Keene,
Duke University, Durham, NC), SmB and SmD (from Joe Craft,
Yale University, New Haven, CT), were cloned into the pQE
expression vectors (Qiagen Inc., Chatsworth, CA) to generate re-
combinant fusion proteins with a 6XHis tag. Mouse Ro52 in
pQE expression vector was a gift from James McCluskey
(Flinders Medical Center, Bedford Park, South Australia). SmA
cDNA in the pET expression vector was a gift from Joe Craft. For
cloning of mouse Ro60 cDNA, two 
 
l
 
gt10 libraries were used: a
mouse liver 5
 
9
 
 stretch plus cDNA library from Clontech (Palo
Alto, CA) and 33BTE-67, a mouse 
 
l
 
-
 
d
 
 T cell hybridoma library
from Rebecca L. O’Brien (National Jewish Medical and Research
Center, Denver, CO). They were screened with a 1.8-kb,
EcoRI/NotI DNA fragment of human Ro60 under nonstringent
conditions. Two independent clones, MuT 10.1 (2-kb insert
from T-cell library) and MuL 23.1 (2.3-kb insert from liver cDNA
library) were obtained from screening 1.2 
 
3
 
 10
 
6
 
 colonies. Their
DNA sequences were determined and data were analyzed using
Eugene (Molecular Biology Information Resource, Baylor Med-
ical College, Houston, TX) and GCG (Wisconsin Package, Ver-
sion 8; Genetic Computer Group, Madison, WI) software. MuT
10.1 and MuL 23.1 had an overlap of 1.446 kb. The combined
sequence of these two clones was 85% homologous to the human
Ro60 sequence. It lacked a 170-bp fragment at the 5
 
9
 
 end. 5
 
9
 
RACE (11) was used to amplify the missing 170-bp fragment.
The entire coding region of mouse Ro60 was generated by PCR
using WEHI 7.1 cDNA and cloned into the KpnI and HindIII
sites of the pQE expression vector. Mouse La was similarly
cloned from the liver cDNA library screened with full-length hu-
man La cDNA. The complete cDNA encoding mouse La was
cloned into pQE expression vector. Recombinant proteins were
expressed in 
 
Escherichia coli.
 
 Recombinant antigens expressed in
pQE vectors were purified under denaturing conditions follow-
ing manufacturer’s instructions. Purified proteins were dialyzed
against distilled water, and stored at 
 
2
 
70
 
8
 
C until use. Recombi-
nant Sm was purified as described by Fatenejad et al. (12).
 
Synthetic Peptides.
 
Overlapping peptides spanning the entire
sequence of hRo60 and mRo60 were synthesized on an auto-
mated peptide synthesizer, AMS 422 (Gilson Inc., Middleton,
WI) using Fmoc Chemistry. Peptides were analyzed and purified
by reverse phase HPLC and their masses confirmed by mass spec-
trometry. Peptides used for immunizations were made in the
Biomolecular Research Facility, University of Virginia.
 
Immunization.
 
6–8-wk-old female SJL/J and A/J (both from
National Cancer Institute, Bethesda, MD) and BALB/cByJ mice
(Jackson Laboratory, Bar Harbor, ME) were maintained in the
animal facility at the University of Virginia. For in vitro lymph
node cell (LNC) proliferative responses, mice were immunized
with either 100 
 
m
 
g of recombinant protein or 50 
 
m
 
g of synthetic
peptide emulsified in complete Freund’s adjuvant (CFA) (Difco
Laboratories, Detroit, MI) in one hind footpad and at the base of
the tail. For analysis of antibody production, animals were immu-
nized initially as described above. They were subsequently im-
munized with 50 
 
m
 
g of antigen emulsified in incomplete Freund’s
adjuvant (Difco Laboratories) intraperitoneally, on days 14 and
28. Controls were immunized with adjuvant alone in a similar
way. Tail bleeds from mice were collected at different time points
postimmunization, and sera were assayed for specific Abs.
 
Lymph Node Proliferation Assays.
 
2 wk after immunization,
draining lymph nodes were removed and single-cell suspensions
were prepared. LNCs were cultured in 96-well plates at 3 
 
3
 
 10
 
5
 
cells/well in DMEM (BioWhittaker Inc., Walkersville, MD)
supplemented with 10% FCS (Hyclone Laboratories, Logan,
UT), 2 mM 
 
l
 
-glutamine, nonessential amino acids, sodium pyru-
vate, 100 U/ml penicillin, 100 
 
m
 
g/ml streptomycin (GIBCO BRL,
Gaithersburg, MD), and 5 
 
3
 
 10
 
2
 
5
 
 M 2-mercaptoethanol, with or
without antigens in triplicates. The cells were incubated at 37
 
8
 
C
in a humidified, 5% CO
 
2
 
 atmosphere for 4 d. Plates were pulsed
with [
 
3
 
H]thymidine (NEN Research Products, Boston, MA), 0.5
 
m
 
Ci/well, during the last 16 h of culture. The cells were har-
vested onto glass fiber filters (Wallac Oy, Turku, Finland) using a
semiautomated cell harvester (Skatron Instruments Inc., Sterling,
VA) and radioactivity measured by liquid scintillation counting
using a Betaplate counter (LKB Instruments Inc., Piscataway,
NJ). The results are expressed, either as stimulation index (SI),
determined by dividing the mean triplicate antigen-specific cpm
by mean triplicate cpm from wells without antigen, or as mean
triplicate 
 
D
 
CPM (mean triplicate cpm with antigen minus mean
triplicate cpm without antigen).
 
ELISA.
 
Microtiter plates, Immulon 2 and Immulon 4 (Dy-
natech Inc., Chantilly, VA) were coated with rRo60 and syn-
thetic peptides, respectively, at a concentration of 2 
 
m
 
g/well, in
carbonate-bicarbonate buffer, pH 9.6, overnight at 4
 
8
 
C. The
wells were then blocked with PBS containing 3% BSA (200 
 
m
 
l/
well). Sera diluted in PBS containing 0.1% Tween 20 (PBST)
and 3% BSA were added to the washed plates. Bound antibodies
were detected with peroxidase-conjugated goat anti–mouse IgG
(Southern Biotechnology Associates Inc., Birmingham, AL), us-
ing the substrate o-phenylenediamine (0.05%) (Sigma Chemical
Co., St. Louis, MO), 0.06% hydrogen peroxide in citrate-phos-
phate buffer, pH 5.0. Reaction was stopped after 15 min by the
addition of 50 
 
m
 
l/well of 2.5 N sulfuric acid. Absorbance was
read at 490 nm. Volumes of the diluted sera, Abs, and substrates
were 100 
 
m
 
l/well, and incubations were for 2 h at room temper-
ature. Plates were washed five times with PBST between steps.
 
Immunofluorescence.
 
HeLa cells or NIH/3T3 cells were grown
on round coverslips (1 cm diameter). The cells were fixed in
methanol for 7 min at 
 
2
 
20
 
8
 
C. Sera diluted in PBS containing 1%
BSA were added. After 2 h, bound antibodies were detected with 
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rhodamine-coupled goat anti–mouse IgG. In between steps, cov-
erslips were washed three times with PBS.
 
Antibody Absorption.
 
Peptides hRo60
 
316–335
 
 and hRo60
 
441–465
 
were coupled to CNBr activated Sepharose 4B beads (Pharmacia
Biotech Inc., Piscataway, NJ) following the manufacturer’s in-
structions. JS7A, a peptide corresponding to amino acids 330–342
of ZP3, which is a protein in the mouse zona pellucida, was also
coupled to beads and used as a control in absorption experiments.
The beads were incubated overnight with PBS containing 3%
BSA at 4
 
8
 
C. Sera were diluted in PBST containing 3% BSA and
incubated with the beads for 2 h at room temperature. The ab-
sorbed sera were assayed for anti-peptide activity in ELISA and
other antibody activity.
 
Western Blotting.
 
WEHI 7.1 cell extract was run on a 7.5%
SDS-PAGE and transferred overnight onto nitrocellulose paper.
After a 5% milk protein blocking step, sera diluted in PBST con-
taining 5% milk protein were incubated with the nitrocellulose
paper. Bound antibodies were detected with peroxidase-labeled
goat anti–mouse IgG, and blots were developed using enhanced
chemiluminescence (Pierce Chemical Co. Rockford, IL). All in-
cubations were for 2 h at room temperature, and blots were
washed with PBST three times in between steps.
 
Slot Blot.
 
The slot blot apparatus from Millipore Inc. (Bed-
ford, MA) was used. Each slot had a length of 8-mm. Purified re-
combinant antigens were loaded at a concentration of 5 
 
m
 
g/slot
in 8 M urea. The 8 mm strips were cut into three equal parts. Af-
ter a blocking step with PBS containing 5% milk protein over-
night at 4
 
8
 
C, the strips were incubated with diluted sera and the
bound Abs were detected in a manner similar to that described in
the preceding paragraph.
 
Immunoprecipitation of mYRNAs Associated with Ro60.
 
The
mYRNAs associated mRo60 were immunoprecipitated as de-
scribed by Craft and Hardin (13). Briefly, WEHI 7.1 cells were
suspended at 2.5 
 
3
 
 10
 
5
 
 cells/ml in phosphate-free RPMI 1640
supplemented with 5% dialyzed FCS. The cells were grown for
14 h in the presence of 10 
 
m
 
Ci/ml of 
 
32
 
P (NEN Research Prod-
ucts). The 
 
32
 
P-labeled RNA associated with Ro60 were immu-
noprecipitated with immune and control sera. The precipitated
RNA were electrophoresed and revealed by autoradiography.
 
Results
 
The Immune Responses to rhRo60 Were Directed to Multiple
T and B Determinants.
 
T and B cell responses to rhRo60
were studied in SJL/J (H-2
 
s
 
), BALB/c (H-2
 
d
 
), and A/J (H-
2
 
a
 
). All three strains mounted a strong T cell proliferative
response to rhRo60 (Fig. 1 A). Strong antibody responses
were also induced. Abs to the immunogen were readily de-
tected 14 d after the initial immunization. By day 30, high
antibody titers were generated and reactivity to rhRo60
was detectable at a serum dilution of 10
 
6
 
 (Fig. 1 B). Con-
trol mice injected with CFA alone did not give specific T
and B cell responses. Two other experiments gave similar
results.
A panel of overlapping peptides spanning the entire se-
quence of hRo60 was made and used to map T and B
epitopes recognized by mice immunized with rhRo60. In
preliminary experiments, peptides at a concentration of 20
 
m
 
M were found to be optimal in recalling T cell responses in
vitro. A peptide was considered to contain a T epitope(s) if it
gave an SI 
 
. 
 
2.0 in at least three independent experiments. Fig.
 
2 A shows representative results for SJL/J mice. Multiple pep-
tides recalled the proliferative response in varying magnitudes.
Peptides hRo60
 
441–465
 
 and hRo60
 
316–335
 
 were the most domi-
nant peptides, followed by peptide hRo60
 
306–325
 
, hRo60
 
26–45
 
,
hRo60
 
401–425
 
, and hRo60
 
481–505
 
. Multiple T cell determi-
nants were also mapped in A/J and BALB/c mice, and the
results are summarized in Fig. 2 B
 
.
Figure 1. Immune response to rhRo60 in SJL/J (circles), A/J (squares),
and BALB/c (triangles) mice immunized with rhRo60. T cell responses
were studied in LNC proliferative assays (A) and antibody responses were
determined by ELISA (B). The LNC proliferative responses are expressed
as mean triplicate DCPM. In A, results are shown for mice immunized
with rhRo60 (open symbols) and with CFA (filled symbols). (B) The
ELISA results are expressed as mean duplicate OD490nm and are shown for
day 14 (ddddd) and day 30 (2) pooled sera. Sera from control mice im-
munized with CFA, gave OD490nm , 0.1 at a serum dilution of 1:100.
Figure 2. Delineation of T cell determinants on hRo60 in mice of dif-
ferent haplotypes. In vitro LNC proliferative responses were recalled,
with synthetic peptides at 20 mM concentration. Results are expressed as
SI, a ratio of the mean triplicate CPM obtained with peptide and the
mean triplicate cpm without peptide. (A) Multiple determinants recog-
nized by SJL/J T cells are present in Ro60. Results are shown as mean
triplicate SI 6 SEM from three independent experiments. Peptides giving
an SI . 2 are marked with an asterisk (*). For comparison, the response
to rhRo60 at a concentration of 3 mg/ml is shown. (B) A summary of T
cell determinants on hRo60, seen by SJL/J, A/J, and BALB/c mice.
Amino acid sequences for peptides giving a SI . 2 are shown. 
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The B cell epitopes on Ro60 were mapped in ELISA,
using microtiter plates coated with synthetic peptides. Fig.
3 shows results for sera obtained on days 14 (closed bars)
and 30 (open bars) after immunization. Three clusters of re-
activities were detected, with most determinants located on
the COOH-terminal region of the molecule (hRo60 amino
acids 401–538). B cell epitopes were also mapped in the
middle portion of the molecule, hRo60 amino acids 240–
315. The sera recognized only two peptides from the NH
 
2
 
-
terminal region. While peptide hRo60
 
1–25
 
 was recognized
by all strains, peptide hRo60
 
61–85
 
 was recognized only in
SJL/J and A/J strains. Similarly, peptides hRo60
 
261–285
 
,
hRo60
 
456–475
 
, and hRo60
 
466–485
 
 were recognized in SJL/J
and A/J but not in BALB/c. Peptide hRo60
 
201–225
 
 appears
to be specific to BALB/c and peptide hRo60
 
316–335
 
 for SJL/J.
 
Both T and B Cell Responses to rmRo60 Were Inducible.
 
Because of a sequence difference between human and
mouse Ro60, the immune response generated by hRo60
immunization could be strongly mediated by these differ-
ences between the xenogeneic and autologous forms of this
autoantigen. To determine whether responses to autolo-
gous Ro60 could be demonstrated, the cDNA encoding
mouse Ro60 was cloned and expressed. Our sequence was
in agreement with that reported by Wang et al. (14). There
is 90% homology at the amino acid level between the
mouse and human Ro60, and the amino acid differences
scatter throughout the whole sequence. Immunization
with purified rmRo60 induced T cell proliferative re-
sponses in all strains of mice (Fig. 4). The response in SJL/J
mice was much higher than that in BALB/c and A/J. Pro-
liferative responses were not seen in the animals immu-
nized with only CFA, indicating specificity of the response.
A set of peptides (20 mers with an overlap of 10) span-
ning the entire sequence of mRo60 was synthesized in or-
der to undertake T cell epitope mapping. Only 3 peptides,
mRo60121–140, mRo60281–300, and mRo60311–330, were able
to recall the proliferative responses in SJL/J after immuni-
zation with rmRo60 (Fig. 5). The most dominant peptide
was mRo60311–330. Interestingly, this peptide overlaps the
dominant T cell determinant mapped in hRo60, peptide
hRo60316–335. These results indicate a lack of tolerance to this
region on the Ro60 antigen. The other dominant epitope
mapped on hRo60 was in peptide hRo60441–465. However,
the mRo60 peptides mRo60441–460 and mRo60451–470 that
span this region could not recall the proliferative responses.
Figure 3. Mapping of B cell determinants on hRo60. Sera from, SJL/J,
A/J, and BALB/c strains of mice (four/group), immunized with rhRo60,
were pooled and reactivity to overlapping synthetic peptides of hRo60
was determined in ELISA. Sera were used at a dilution of 1:500. Results
are expressed as mean duplicate OD490nm and are shown for sera obtained
on day 14 (j) and day 30 (h) after immunization. Sera obtained from mice
immunized with CFA alone gave a OD490nm , 0.05 at 1:500 dilution.
Figure 4. T cell proliferative responses to rmRo60 in mice of different
haplotypes: SJL/J (d rmRo60, s CFA), A/J (j rmRo60, h CFA), and
BALB/c (. rmRo60, , CFA). Results are expressed as mean triplicate
DCPM. Data for SJL/J strain of mice are represented on the left y-axis.
Data for A/J and BALB/c mice are plotted on the right y-axis.
Figure 5. Mapping of T and B cell determinants on mRo60. (A) In
vitro T cell proliferative responses were recalled with synthetic peptides
of mRo60, at 20 mM concentration. Results are expressed as mean of
SI 6 SEM from three independent experiments. A mean SI . 2.0 was
considered positive. For comparison, the response to rmRo60 at a con-
centration of 10 mg/ml is included. (B) Reactivity of pooled sera (day 67)
at a dilution of 1:500, was checked with synthetic peptides of mRo60 in
ELISA. Results are expressed as mean duplicate OD490nm.535 Deshmukh et al.
The panel of peptides was also used to map B cell deter-
minants on mRo60. As shown in Fig. 5 B, multiple pep-
tides reacted with the pooled sera at day 67 postimmuniza-
tion. These B cell determinants are present throughout the
whole span of mRo60. Immune sera at later time points
gave similar reactivity patterns.
Both Xenogeneic rhRo60 and Autologous rmRo60 Induced
Intermolecular Determinant Spreading. Sera from SJL mice
immunized with rmRo60 and rhRo60 were positive for
antinuclear antibodies (ANA) (Fig. 6, A and B, respec-
tively). Although results are shown for pooled sera, all mice
had ANA in their sera. Such antibodies were not detected
in mice immunized with only CFA (Fig. 6 C).
All mice immunized with either rmRo60 or rhRo60
produced high titers of Abs to the immunogens. In
both groups of mice, immunoprecipitating Abs to native
mRo60 were induced (data not shown). In addition to ex-
pected reactivity to La and Ro52 (5–9), Abs to SmA, SmB,
SmD, and U1RNP associated 70 kD protein were also ob-
served (Fig. 7). In the control mice immunized with CFA,
only weak reactivity to La, SmD, and U1RNP associated
70 kD protein was observed in two of seven mice studied.
Surprisingly, recombinant dihydrofolate reductase (DHFR)-
6XHis protein included as a control protein was reactive
with some of the immune sera. As presented later, this re-
activity was also found in some of the sera from mice im-
munized with either human or mouse Ro60316–335, which
do not have the 6XHis tag. Thus it is concluded that this
reactivity was not directed against the 6XHis tag. Similar
results were obtained in an additional experiment. These re-
sults suggest that intermolecular epitope spreading had oc-
curred in mice immunized with either rhRo60 or rmRo60.
Intermolecular and Intramolecular Antibody Diversification Is In-
duced by Peptide hRo60316–335 but Not by Peptide hRo60441–465.
The presence of multiple T and B epitopes on both
rhRo60 and rmRo60 makes it difficult to address the phe-
nomenon of spreading and the mechanisms involved due
to the complexity of the immune response elicited. For this
purpose, we used synthetic peptides representing the domi-
nant T cell epitopes on hRo60 as immunogens.
Sera from mice immunized with peptide hRo60316–335
had very high titers of antipeptide Abs. The titers peaked
between days 60 and 90. In addition, Abs to nonhomolo-
gous peptide hRo60401–425 were detected as early as 24 d af-
ter immunization. The titer against hRo60401–425 increased
with time up to 60 d postimmunization. With time, the
immune sera had increasing amounts of Abs with more di-
verse specificities. These sera were capable of immunopre-
cipitating native Ro60 as shown in Fig. 8. Two cytoplas-
mic RNA moieties, namely mY1 and mY3 associated with
mRo60 (15), have been shown to be precipitated by Ro-
specific antisera. The appearance of Abs to the nonhomol-
ogous peptide and to the native Ro60 determinant(s) rep-
resents intramolecular determinant spreading in response to
the immunization with the peptide hRo60316–335.
Antibody diversification to multiple intracellular deter-
minants was also evident in that the pooled immune sera
recognized multiple cellular proteins in WEHI 7.1 cell ex-
tract in Western blot analysis (Fig. 9). Of particular interest
was the protein recognized at 48 kD (Fig. 9, lanes 2–4),
which was also recognized by the CDC anti-La reference
serum (Fig. 9, lane 1), suggesting that intermolecular
epitope spreading to La might have occurred. This reactiv-
Figure 6. Induction of ANAs
following immunization with
Ro60 antigens. Sera obtained on
day 67, postimmunization, were
pooled and used at a dilution of
1:200 to stain methanol-fixed
HeLa cells (detected by indirect
immunofluorescence). a, b, and c
represent sera from mice immu-
nized with rmRo60, rhRo60,
and CFA, respectively.
Figure 7. Intermolecular determinant spreading of antibody responses
in SJL/J mice immunized with Ro60 antigens. Reactivities of sera with
different ribonucleoproteins are shown in slot blots. Each lane represents a
serum sample at a dilution of 1:250.
Figure 8. Immunoprecipitation of mYRNAs associated with mRo60.
WEHI 7.1 cells were labeled with 32P, and RNA species were immuno-
precipitated and visualized by autoradiography. Lanes 1–4 represent
pooled sera on days 24, 37, 60, and 90, respectively, from SJL/J mice im-
munized with hRo60316–335. Lanes 5–7, represent pooled sera on days 37,
60, and 90, respectively, from mice immunized with CFA. Lane 8 is con-
trol, without any serum, and lane 9 is a human anti-Ro60 reference se-
rum from the Center for Disease Control.536 Immune Responses to Ro60 and Its Peptides
ity was not observed in adjuvant immunized mice (Fig. 9,
lanes 5–7). These immune sera also reacted with additional
protein bands at both high and low molecular weight
ranges. Based on this result, the identity of the proteins rec-
ognized by these sera can only be speculated on. To iden-
tify other autoantigens, the sera were checked for reactivity to
purified recombinant ribonucleoproteins in slot blots (Fig.
10). All sera reacted strongly with rmRo60. Interestingly, re-
activity to La, SmD, and U1RNP associated 70 kD protein
was also detected. In a few mice, reactivity to DHFR was
observed. However, no reactivity to Ro52 and SmB, which
have a 6XHis tag, was observed. Immunization of mice with
a control peptide JS7A did not generate antibodies reactive
with these proteins, although very weak reactivity to Ro60
was observed in two of six control mice (Fig. 10).
The diversification of the autoreactivity in response to
the immunization with hRo60316–335 was further docu-
mented in our indirect immunofluorescence study. Anticy-
toplasmic and antinuclear Abs appeared shortly after im-
munization. More remarkable was the appearance of a
population of Abs that stained the Golgi complex (Fig. 11);
the anti-Golgi staining was not seen in HeLa cells treated
with brefeldin A, which disrupts the architecture of Golgi
apparatus (16). Similar results were obtained when a mouse
cell line, NIH/3T3, was used as the substrate. Sera from
control mice did not give similar staining.
Antibodies reactive to mRo60 epitopes not related to
peptide hRo60316–335 were generated in mice immunized
with the peptide (Fig. 12). Sera were absorbed with the
immunogen to deplete them of antipeptide antibodies.
These sera still recognized rmRo60 in ELISA, indicative of
intramolecular epitope spreading (Fig. 12 A). Absorption of
sera with a control peptide JS7A had little effect on the
reactivity of sera, either to the peptide or to rmRo60 (Fig.
12 A). Results presented in Figs. 8–12 were representative
of three experiments.
The immune response against hRo60441–465, which con-
tains a dominant T cell epitope of hRo60, was markedly
different than that against peptide hRo60316–335. Immuniza-
tion with peptide hRo60441–465 generated very high titers
Figure 9. Reactivity of pooled immune
sera with WEHI 7.1 cell extracts in Western
blot. Each lane was loaded with protein
equivalent to 2.5 3 106 cells. Pooled sera
were used at a dilution of 1:100. Lane 1,
human anti-La reference serum from CDC;
lanes 2–4, day 37, 60, and 90 sera from mice
immunized with peptide hRo60316–335; lanes
5–7, days 37, 60, and 90 sera from mice im-
munized with CFA.
Figure 10. Intermolecular determinant spreading of antibody responses
in SJL/J mice immunized with hRo60 peptides. Reactivity of sera from
mice immunized with peptides hRo60316–335, hRo60441–465, and ZP3 pep-
tide JS7A, with different ribonucleoproteins was tested in slot blots. Each
lane represents an individual serum, at a dilution of 1:250.
Figure 11. Anti-Golgi staining patterns of antibodies generated by
hRo60316–335 immunization. HeLa cells grown on coverslips and fixed in
methanol were used as substrate. Results are shown for pooled sera (day
60) used at a dilution of 1:200.
Figure 12. Intramolecular diversification of antibody responses against
mRo60 following immunization with synthetic peptides. Pooled sera
from mice immunized either with hRo60316–335 peptide (A), or
hRo60441–465 peptide (B) were absorbed with their respective immuno-
gens and peptide JS7A. Reactivity of unabsorbed and absorbed sera with
peptides and rmRo60 was determined in ELISA. Results are expressed as
mean duplicate OD490nm. Open bars denote unabsorbed pooled sera.
Cross bars denote pooled sera, absorbed with peptide JS7A. The hatched
bars denote pooled sera absorbed with hRo60316–335 in (A) and with
hRo60441–461 in (B).537 Deshmukh et al.
(105–106) of antibodies reactive with the peptide in ELISA.
Although these antibodies reacted with rmRo60 in ELISA
(Fig. 12 B), they did not immunoprecipitate native mRo60
(data not shown). Analysis of antibody reactivities in slot
blots (Fig. 10) showed reactivity with rmRo60 in all ani-
mals and reactivity to rmRo52 and SmA in only one out of
five animals. No reactivity was observed to La, SmB, SmD,
U1RNP associated 70 kD protein, and DHFR. Absorption
of pooled sera with the immunogen abolished reactivity to
the peptide and all reactivity to rmRo60 as shown in Fig.
12 B. Similar results were obtained in two additional ex-
periments involving 10 mice.
Peptide mRo60316–335 Was a Dominant T Cell Epitope,
Whereas mRo60441–465 Was a Cryptic T Cell Epitope. The
possibility that the difference observed between the im-
mune responses to the two immunodominant T cell pep-
tides on hRo60 might be due to lack of presentation of the
autologous mRo60441–465 was suggestive from data shown
in Fig. 5 A. Peptide mRo60311–330 (overlaps hRo60316–335)
was able to recall the LNC proliferative response in mice
immunized with rmRo60, whereas peptides mRo60441–430
and mRo60451–470 failed to do so. This was further ex-
plored. Peptides mRo60316–335 and mRo60441–465 were
made and used to recall the LNC proliferative responses
in mice immunized with rmRo60. Fig. 13 shows repre-
sentative results from one of three experiments. While pep-
tide mRo60316–335 could recall the proliferative response,
mRo60441–465 could not, indicating that the T cell epitope
in the latter peptide is cryptic.
Despite the three amino acid differences between
hRo60316–335 and mRo60316–335, the T cell epitopes in these
two peptides were cross-reactive. Peptide mRo60316–335
was able to recall proliferative responses in mice immu-
nized with the homologous human peptide (Fig. 14 A),
and vice versa (Fig. 14 B). In both cases, the proliferative
responses were recalled by the recombinant Ro60 proteins,
further confirming the noncryptic nature of the auto T
epitope in the peptide mRo60316–335.
LNC proliferative responses were induced by immuniza-
tion with both peptides hRo60441–465 and mRo60441–465
(Fig. 14, C and D). However, these responses were sig-
nificantly lower than those observed for the peptides,
hRo60316–335 and mRo60316–335. At best, very weak cross-
reactivity was observed between the peptides hRo60441–465
and mRo60441–465. Immunization of mice with the
mRo60441–465 peptide induced a weak proliferative re-
sponse with SI at 2–4. In addition, rmRo60 was not able to
recall this response. The weak cross-reactivity between the
mouse and human peptides is likely due to the more exten-
sive differences in their amino acid sequences.
Homologous Peptide mRo60316–335 Induced Antibody Diversi-
fication. Immunization of mice with peptide mRo60316–335
resulted in high titers of anti-peptide antibodies, capable of
immunoprecipitating native mRo60. Reactivity to La,
SmD, and U1RNP associated 70-kD protein and DHFR
was observed in slot blots (Fig. 15 A) indicative of intermo-
lecular epitope spreading. The reactivity patterns of the im-
mune sera were similar to those of sera of mice immunized
with the human peptide (Figs. 7 and 15 B). With respect to
intramolecular spreading, absorption of sera with the im-
munogen had little effect on the reactivity to Ro60 al-
though almost all reactivity to the peptide was abolished
(Fig. 15 C). Absorption with control peptide JS7A had no
effect, either on the reactivity with the peptide or with the
whole antigen. It is of interest to note that these immune
sera did not stain the Golgi complex. Similar results were
obtained in an additional experiment.
Discussion
Ro60 (SS-A) was initially described by Clark et al. (17)
as Ro and by Alspaugh and Tan (18) as SS-A. Later it was
documented that Ro and SS-A were identical (19). Ro
(SS-A) is a 60-kD protein that is thought to be associated
with La through their binding to a common set of hY-
RNAs (20). Autoantibodies to Ro52 are commonly found
Figure 13. Recall of in vitro
LNC proliferative responses by
rmRo60 (open bars) and peptides,
mRo60316–335 (cross bars) and
mRo60441–465 (hatched bars), in mice
immunized with rmRo60. Results
are expressed as mean triplicate SI.
And an SI . 2.0 was considered
positive.
Figure 14. Cross priming between human and mouse peptides. SJL/J
mice were immunized with peptides: hRo60316–335 (A), mRo60316–335 (B),
hRo60441–465 (C), and mRo60441–465 (D). 2 wk later, proliferative re-
sponses were recalled with peptides hRo60316–335 (d), mRo60316–335 (s),
hRo60 (m), mRo60 (n), hRo60441–465 (j), and mRo60441–465 (h). Re-
sults are expressed as mean triplicate SI. y-axis scales for A, B and C, D
are different. Peptide concentrations are in mM and those for Ro60 in
mg/ml as shown in the x-axis.538 Immune Responses to Ro60 and Its Peptides
in patients with anti-Ro60 and/or anti-La autoantibodies.
The absence of physical association between Ro60 and
Ro52 has been shown (21). The presence of autoantibod-
ies to Ro60 has been associated with SLE, Sjögren’s
syndrome, neonatal lupus, primary biliary cirrhosis, and
chronic active hepatitis. Antibodies against Ro60 have
been found in a substantial number of normal individuals,
many of whom have been identified after their children
were diagnosed with neonatal lupus (4). In addition, a con-
siderable number of patients with only a mild inflammatory
arthritis also have anti-Ro60 Ab. Thus the understanding
of the autoimmune response to Ro60 has significant impli-
cations in our understanding of autoimmunity and the
pathogenesis of SLE.
In this study, T and B cell responses to multiple determi-
nants within Ro60 have been induced by immunization
with either human or autologous recombinant Ro60 in
multiple non–lupus-prone strains of mice (Figs. 2, 3, and
5). It is of interest that antinuclear Abs are generated in the
immunized mice (Fig. 6). In addition, Abs to La, Ro52,
and peptides associated with the snRNP particles are also
generated (Fig. 7). The generation of Abs to La and Ro52
is anticipated because of the clinical impression that re-
sponses to these two antigens are often linked to the anti-
Ro60 response. In addition, other investigators have re-
ported that Abs to these three antigens are detected in the
sera from mice immunized with any one of these three au-
toantigens. However, the detection of Abs to Sm peptides
and 70-kD U1-RNP is unexpected. Thus, the autoanti-
body responses to immunizations with both xenogeneic
and autologous Ro60 target a much broader range of au-
toantigens. The involvement of Sm and U1-RNP peptides
as targets in the anti-Ro60 response would provide impetus
to reexamine some of the current impressions and hypoth-
eses regarding the genesis of SLE-related autoantibodies.
Specifically, the clinical impression that SLE-related Abs
react to linked sets of autoantigens, i.e., Ro60 and La, Sm
and U1-RNP (snRNPs), and histones and DNA (22, 23)
should be revisited. The “particle hypothesis” (24), which
was postulated to explain the occurrence of autoantibodies
in linked sets, and which states that chromatin, snRNPs,
and Ro/La complexes are available, as intact particles to the
immune system, should be scrutinized.
The identification of multiple T cell determinant con-
taining peptides in both human and mouse Ro60 allows us
to explore the immunogenicity of dominant and subdomi-
nant T cell determinants of this auto antigen. Ro60316–335
has both T and B cell determinants. Although there are
three amino acid differences between the xenogeneic and
autologous peptides, both peptides have dominant T cell
determinants for multiple strains of mice. Both human and
mouse peptides induce a T cell proliferative response, and
the intact recombinant proteins recall the induced T cell
responses (Fig. 14). These peptides have cross-reactive T
cell epitopes and they recall T cell responsiveness induced
by the recombinant Ro60 proteins (Figs. 2 and 13). By the
criteria of Sercarz et al. (25), the T cell epitopes in the xe-
nogeneic and the autologous peptides should be considered
immunodominant. In addition, these peptides induce a di-
verse autoantibody response to multiple autoantigens. The
targets for the diversification of the autoantibody responses
include La, SmD, 70-kD U1-RNP, and other unidentified
intracellular constituents (Figs. 9–11). Although only the
data on SJL/J are presented here, we found similar but not
identical data in A/J and BALB/c. Thus, a dominant T cell
determinant of an autoantigen need not be tolerogenic.
The hierarchical self-tolerance to T cell determinants dem-
onstrated in La (SS-B) (6) may not be generalized to other
autoantigens readily.
Although human Ro60441–465 has a dominant T cell
epitope for SJL (Fig. 2), the homologous mouse peptide can-
not recall the anti-hRo60441–465 T cell response (Fig. 13). In
addition, the autologous peptide appears to be cryptic in that
it induces a weak T cell response to the immunogen and
that the induced response cannot be recalled with the intact
mouse Ro60 (Fig. 14). It is of interest to note that human
Ro60441–465 induces only very limited autoantibody response
to the immunizing peptides with little diversification to other
autoantigens. This observation and the diverse autoantibody
response induced by either human or mouse Ro60316–335 sup-
port the hypothesis that only immune responses to auto–T
cell epitopes that can be generated by processing and presen-
tation of the endogenous antigen lead to a diversified autoan-
tibody response (6, 26). This hypothesis suggests a mechanism
in which endogenous autoantigens play a significant role in
the diversification of the autoantibody responses by relevant
self-peptides and provides an explanation for the inability
of certain self-peptides of SLE-related autoantigens such as
Ro60441–465, certain La (6), and Sm (27) peptides to induce a
diverse autoantibody response.
There are differences in the antibody specificities in the
immune sera from mice immunized with the recombinant
Figure 15. Induction of anti-
body diversification in mice immu-
nized with peptide mRo60316–335.
(A) Reactivity of day 30 sera
from four mice with different ri-
bonucleoproteins was tested in
slot blots. All sera were tested at
1:250 dilution. (B) Reactivity of
pooled sera from SJL/J mice im-
munized with hRo60316–335 pep-
tide (lane 1), JS7A (lane 2), and
CFA (lane 3). (C) Pooled sera
from mice immunized with
mRo60316–335 were absorbed
with the immunogen (hatched
bars) and control peptide JS7A
(cross bars). The reactivities of
the unabsorbed (open bars) and
the absorbed sera were deter-
mined in ELISA with either
mRo60316–335 (left) or mRo60
(right) as the target antigen. The
sera absorbed with the immuno-
gen did not react with the im-
munogen mRo60316–335 while
the reactivity with mRo60 re-
mained. Results are expressed as
mean duplicate OD490nm.539 Deshmukh et al.
Ro60 proteins and those immunized with Ro60316–335.
The immune sera of mice immunized with recombinant
Ro60 are reactive with Ro52, SmA, and SmB, whereas
those from mice immunized with Ro60316–335 are not reac-
tive. Immune sera from mice immunized either with
whole Ro60 protein or the peptide Ro60316–335 have Abs
to native Ro60 as demonstrated by immunoprecipitation of
the associated mYRNAs. In addition, absorption experi-
ments show that the immune sera from mice immunized
with Ro60316–335 have Abs to determinants elsewhere in
Ro60. These data are not in congruency with the particle
hypothesis as discussed previously. If the particle hypothesis
(24) is operative in our system, the differences in the fine
specificities of the autoantibodies generated by immuniza-
tions with the intact protein and the peptide should not be
significantly different. In addition, these data also suggest
the presence of an antigenic peptide or peptides within the
Ro60 molecule, which can induce autoantibodies reactive
with Ro52, SmA, and SmB. Studies with peptides contain-
ing dominant T cell epitopes within either human or
mouse Ro60 may provide data to support this thesis.
The generation of anti-Golgi Ab in mice immunized
with human Ro60316–335 but not in mice immunized with
human Ro60, mouse Ro60, or mouse Ro60316–335 requires
some comments. The anti-Golgi Ab cannot be absorbed by
mouse Ro60 or mouse Ro60316–335. In addition, human
Ro60 cannot inhibit the staining. However, the human
peptide blocks the staining completely. Further experi-
ments to be presented elsewhere (28) indicate that there is a
cross-reactive B cell epitope shared between the Golgi
complex and the human peptide. These data indicate that
the immunogen determines the specificity of the Ab gener-
ated even in the immune responses involving autoantigens.
From the above discussion, the nature of the immuno-
gen is an important factor in determining the specificities of
the autoimmune response in our system. This importance
is further underscored by our early experience using syn-
thetic peptides as the immunogen. During the early stage of
our investigation, synthetic peptides were used as the im-
munogen without HPLC purification after they were
made. These crude peptides induced Abs to Ro52 consis-
tently, in addition to those autoantigens targeted by the im-
mune response to the purified peptides. It is apparent that a
contaminating peptide(s) was responsible for the induction
of an antibody response with this specificity. This observa-
tion has led us to prepare our immunizing peptides care-
fully to assure the peptides are .95% in purity. In this re-
gard, multiple antigenic peptides (MAPs) have frequently
been used to induce autoantibodies and to study determi-
nant spreading and autoimmunity (9, 29–31). In the con-
struction of these MAPs, the purity of the peptides is not
assured. More importantly, it is likely that these peptides
may contain multiple T and B cell epitopes other than
those specified by the amino acid sequences, the structure
of which are not readily apparent. For example, recently
the use of MAP of PPPGMRPP, a B cell epitope of SmB/B9
as the immunogen, has led to the conclusion that B cell
epitope spreading is not H-2 restricted in mice (30). Differ-
ential antigen processing and presentation of the immuno-
gen MAP by two strains of mice sharing a similar H-2 re-
gion may result in T cell responses to different epitopes
which may induce autoantibodies with differing specifici-
ties, providing an appearance of non-H2 restriction. Thus,
experimental data involving MAP as the immunogen in the
study of autoimmunity should be interpreted with caution.
In the present study, evidence has been presented that au-
toantibody diversification occurs through a process termed
determinant spreading (32, reviewed in 10, 33–35). Both
intramolecular and intermolecular epitope spreading oc-
curs. Careful absorption experiments to be reported else-
where (28) indicate that similar conformational epitopes
are present in many of the SLE-related autoantigens. With
peptide Ro60316–335 as the immunogen, considerable amounts
of anti-Ro60 autoantibodies cannot be readily absorbed by
the immunogen, indicating that intramolecular determi-
nant spreading occurs by generating specific Ab to Ro60
determinants not present in the immunogen. In contrast,
the immunogen can absorb almost completely the Ab to
La, SmD, and 70 kD U1-RNP. The latter result indicates
that intermolecular determinant spreading may be due to
the generation of distinct populations of autoantibodies to
the conformational epitopes shared in varying degrees
among these autoantigens. Thus, there appears to be a
qualitative difference between intramolecular determinant
spreading and intermolecular spreading in our system. In
addition, molecular mimicry may play an important role in
the diversification of an autoimmune response in SLE.
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